- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05392699
ABOD2011 bij patiënten met vergevorderde solide tumoren na standaard systemische therapie
Een open-blind dosisescalatieonderzoek om de veiligheid, verdraagbaarheid en voorlopige werkzaamheid van ABOD2011 te beoordelen bij patiënten met vergevorderde solide tumoren na standaard systemische therapie
Based on the activation and regulation of immune system by cytokines, mRNA encoding cytokines has become one of the important directions of mRNA tumor drug development. This product (ABOD2011) is a new generation mRNA product for intratumoral injection.
The primary objective of this study is to assess the safety and tolerability, of ABOD2011 in patients with advanced solid tumors that progressed after standard systemic therapy.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
-
Beijing, China
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- 18 years and older.
- Understand and voluntarily sign the informed consent form (ICF).
- Histopathologically confirmed recurrent or metastatic solid tumors.
- Failure of prior systemic standard of care, or intolerance to severe toxicity, or lack of standard of care.
- Presence of at least one measurable lesion as assessed by RECIST Version 1.1.
- At least one superficial or deep lesion for intratumoral administration and biopsy.
- Sufficient organ functions.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.
- Weight > 30 kg.
- Expected survival longer than 12 weeks.
- Evidence of menopause in female patients, or for women of childbearing potential: negative for urine or blood pregnancy.
Exclusion Criteria:
- Any systemic anti-tumor therapy, within 28 days prior to the first dose.
- Radiotherapy within 14 days prior to first dose.
- Use of immunosuppressants.
- Major surgery within 28 days.
- Inadequately controlled diseases.
- Active autoimmune and inflammatory diseases.
- Clinically symptomatic central nervous system tumors or metastases.
- Toxicity of prior anti-tumor therapy is still NCI-CTCAE ≥ 2.
- Other malignancies within the previous 5 years with the exception of cured basal cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the breast, and carcinoma in situ of the cervix.
- Active infections.
- Other conditions that may increase the risk associated with the study drug, or affect the study compliance, etc., which, in the opinion of the investigator, are not suitable for participation in the study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Human single chain IL-12 mRNA-single dose
Human single chain IL-12 mRNA-single dose |
human single chain IL-12 mRNA administered as specified in the treatment arm with injection once only |
|
Experimenteel: Human single chain IL-12 mRNA-multiple dose
Human single chain IL-12 mRNA-multiple dose |
human single chain IL-12 mRNA administered as specified in the treatment arm with injection once per week for 3 weeks |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of Participants Experiencing dose-limiting toxicities (DLTs)
Tijdsspanne: From first dose to Day 28
|
Number of Participants Experiencing dose-limiting toxicities (DLTs) |
From first dose to Day 28
|
|
Number of Participants Experiencing Adverse Events (AEs)
Tijdsspanne: From signed ICF until the date of last visit or start new antitumor therapy, whichever comes first, assessed up to 36 months
|
Number of Participants Experiencing Adverse Events (AEs) |
From signed ICF until the date of last visit or start new antitumor therapy, whichever comes first, assessed up to 36 months
|
|
Number of Participants Experiencing Severe Adverse Events (SAEs)
Tijdsspanne: From signed ICF until the date of last visit or start new antitumor therapy, whichever came first, assessed up to 24 months
|
Number of Participants Experiencing Severe Adverse Events (SAEs) |
From signed ICF until the date of last visit or start new antitumor therapy, whichever came first, assessed up to 24 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Overall Response Rate (ORR)
Tijdsspanne: Up to 36 months
|
Overall Response Rate (ORR) |
Up to 36 months
|
|
Disease Control Rate(DCR)
Tijdsspanne: Up to 36 months
|
Disease Control Rate(DCR) |
Up to 36 months
|
|
Duration of Response (DOR)
Tijdsspanne: Up to 36 months
|
Duration of Response (DOR) |
Up to 36 months
|
|
Progression-Free Survival (PFS)
Tijdsspanne: Up to 36 months
|
Progression-Free Survival (PFS) |
Up to 36 months
|
|
Overall Survival
Tijdsspanne: Up to 36 months
|
Overall Survival |
Up to 36 months
|
|
Maximum observed concentration (Cmax) of ABOD2011
Tijdsspanne: From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
Maximum observed concentration (Cmax) of ABOD2011 |
From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
|
Area under the concentration-time curve (AUC) of ABOD2011
Tijdsspanne: From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
Area under the concentration-time curve (AUC) of ABOD2011 |
From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
|
Maximum observed concentration (Cmax) of IL-12
Tijdsspanne: From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
Maximum observed concentration (Cmax) of IL-12 |
From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
|
Area under the concentration-time curve (AUC) of IL-12
Tijdsspanne: From first dose of ABOD2011 through to 28 days after last dose of investigational product.
|
Area under the concentration-time curve (AUC) of IL-12 |
From first dose of ABOD2011 through to 28 days after last dose of investigational product.
|
|
Plasma concentration of IFN gamma
Tijdsspanne: From first dose of ABOD2011 through to 28 days after last dose of investigational product.
|
Plasma concentration of IFN gamma |
From first dose of ABOD2011 through to 28 days after last dose of investigational product.
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Ning Li, Doctor, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- ABOD2011-001
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .